- Home
- AUID vs CNTX Comparison
AUID vs CNTX Comparison
Compare AUID & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUID
- CNTX
- Stock Information
- Founded
- AUID 2009
- CNTX 2015
- Country
- AUID United States
- CNTX United States
- Employees
- AUID N/A
- CNTX N/A
- Industry
- AUID Computer Software: Prepackaged Software
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- AUID Technology
- CNTX Health Care
- Exchange
- AUID Nasdaq
- CNTX Nasdaq
- Market Cap
- AUID 74.1M
- CNTX 78.0M
- IPO Year
- AUID N/A
- CNTX 2021
- Fundamental
- Price
- AUID $3.78
- CNTX $0.84
- Analyst Decision
- AUID
- CNTX Strong Buy
- Analyst Count
- AUID 0
- CNTX 5
- Target Price
- AUID N/A
- CNTX $5.50
- AVG Volume (30 Days)
- AUID 92.5K
- CNTX 197.0K
- Earning Date
- AUID 08-07-2025
- CNTX 08-06-2025
- Dividend Yield
- AUID N/A
- CNTX N/A
- EPS Growth
- AUID N/A
- CNTX N/A
- EPS
- AUID N/A
- CNTX N/A
- Revenue
- AUID $1,025,363.00
- CNTX N/A
- Revenue This Year
- AUID N/A
- CNTX N/A
- Revenue Next Year
- AUID N/A
- CNTX N/A
- P/E Ratio
- AUID N/A
- CNTX N/A
- Revenue Growth
- AUID 230.96
- CNTX N/A
- 52 Week Low
- AUID $3.68
- CNTX $0.49
- 52 Week High
- AUID $10.21
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- AUID 35.65
- CNTX 64.84
- Support Level
- AUID $3.83
- CNTX $0.82
- Resistance Level
- AUID $4.20
- CNTX $0.87
- Average True Range (ATR)
- AUID 0.38
- CNTX 0.07
- MACD
- AUID -0.02
- CNTX 0.01
- Stochastic Oscillator
- AUID 5.85
- CNTX 58.27
About AUID authID Inc.
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.